PMID- 30806030
OWN - NLM
STAT- MEDLINE
DCOM- 20200421
LR  - 20231104
IS  - 2051-817X (Electronic)
IS  - 2051-817X (Linking)
VI  - 7
IP  - 4
DP  - 2019 Feb
TI  - The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the 
      streptozotocin-induced diabetic mouse kidney proteome.
PG  - e13994
LID - 10.14814/phy2.13994 [doi]
LID - e13994
AB  - In diabetes mellitus (DM), the kidneys are exposed to increased levels of 
      hyperglycemia-induced oxidative stress. Elevated amounts of reactive oxygen 
      species (ROS) are believed to provoke ultrastructural changes in kidney tissue 
      and can eventually result in DM late complications such as diabetic nephropathy. 
      While it is reported that glucagon-like peptide 1 receptors (GLP-1R) are present 
      in the kidney vasculature, the effects of GLP-1 on the kidney proteome in DM is 
      not well described. Thus, we set out to investigate potential effects on the 
      proteomic level. Here the effects of GLP-1R agonism using the GLP-1 analogue 
      liraglutide are studied in the kidneys of streptozotocin (STZ)-treated mice 
      (n = 6/group) by label-free shotgun mass spectrometry (MS) and targeted MS. 
      Unsupervised and supervised multivariate analyses are followed by one-way ANOVA. 
      Shotgun MS data of vehicle and liraglutide-treated mouse groups are separated in 
      the supervised multivariate analysis and separation is also achieved in the 
      subsequent unsupervised multivariate analysis using targeted MS data. The mouse 
      group receiving the GLP-1R agonist liraglutide has increased protein abundances 
      of glutathione peroxidase-3 (GPX3) and catalase (CATA) while the abundances of 
      neuroplastin (NPTN) and bifunctional glutamate/proline-tRNA ligase (SYEP) are 
      decreased compared to the STZ vehicle mice. The data suggest that GLP-1R agonism 
      mainly influences abundances of structurally involved proteins and proteins 
      involved in oxidative stress responses in the STZ mouse kidney. The changes could 
      be direct effects of GLP-1R agonism in the kidneys or indirectly caused by a 
      systemic response to GLP-1R activation.
CI  - (c) 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on 
      behalf of The Physiological Society and the American Physiological Society.
FAU - Liljedahl, Leena
AU  - Liljedahl L
AUID- ORCID: 0000-0003-0444-5296
AD  - Department of Immunotechnology, Lund University, Lund, Sweden.
FAU - Pedersen, Maiken H
AU  - Pedersen MH
AD  - Novo Nordisk A/S, Malov, Denmark.
FAU - McGuire, James N
AU  - McGuire JN
AD  - Novo Nordisk A/S, Malov, Denmark.
FAU - James, Peter
AU  - James P
AD  - Department of Immunotechnology, Lund University, Lund, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Physiol Rep
JT  - Physiological reports
JID - 101607800
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Proteome)
RN  - 0 (neuroplastin protein, mouse)
RN  - 839I73S42A (Liraglutide)
RN  - EC 1.11.1.- (Gpx3 protein, mouse)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 6.1.1.- (Amino Acyl-tRNA Synthetases)
SB  - IM
MH  - Amino Acyl-tRNA Synthetases/genetics/metabolism
MH  - Animals
MH  - Catalase/genetics/metabolism
MH  - Diabetes Mellitus, Experimental/genetics/*metabolism
MH  - Diabetic Nephropathies/genetics/*metabolism
MH  - Glucagon-Like Peptide-1 Receptor/antagonists & inhibitors
MH  - Glutathione Peroxidase/genetics/metabolism
MH  - Hypoglycemic Agents/*pharmacology
MH  - Kidney/*drug effects/metabolism
MH  - Liraglutide/*pharmacology
MH  - Male
MH  - Membrane Glycoproteins/genetics/metabolism
MH  - Mice
MH  - Proteome/*drug effects/genetics/metabolism
PMC - PMC6389751
OTO - NOTNLM
OT  - Diabetic kidney damage
OT  - GLP-1R agonist
OT  - kidney proteome
OT  - liraglutide
COIS- Novo Nordisk markets liraglutide for the treatment of diabetes and obesity. MHP 
      and JNM are full-time employees of Novo Nordisk and hold minor share portions as 
      part of their employment. LL is a former employee of Novo Nordisk and holds minor 
      share portions.
EDAT- 2019/02/26 06:00
MHDA- 2020/04/22 06:00
PMCR- 2019/02/25
CRDT- 2019/02/27 06:00
PHST- 2018/08/08 00:00 [received]
PHST- 2019/01/02 00:00 [accepted]
PHST- 2019/02/27 06:00 [entrez]
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2020/04/22 06:00 [medline]
PHST- 2019/02/25 00:00 [pmc-release]
AID - PHY213994 [pii]
AID - 10.14814/phy2.13994 [doi]
PST - ppublish
SO  - Physiol Rep. 2019 Feb;7(4):e13994. doi: 10.14814/phy2.13994.